The need to reduce health care costs, improve outcomes, and increase access to remote care are intensifying the focus on patient care delivery in the home setting. As a result, pharma companies are seeking alternate delivery systems that can provide patient autonomy and mobility while delivering treatment outside of the clinic. Programmable, variable dose onbody injectors provide such options.

With the introduction of BD Evolve™ Onbody Injector, BD gives pharma companies a wearable solution that is designed to enable new delivery formats in alternate settings. BD Evolve™ enables effective SubQ administration of up to 3 mL of medication. It provides greater flexibility for adjustments to existing formulations and variations in treatment regimens with up to threeday wear, thus allowing for convenient athome medication delivery which may improve adherence, reduce the cost of delivery, and optimize the standard of care.

BD partners with you to develop selfinjection systems that enable drug administration across a range of volumes and viscosities, leveraging BD primary container technology and expertise with a focus on reaching the market faster.

https://drugdeliverysystems.bd.com/co...

BD, the BD Logo and Evolve are trademarks of Becton, Dickinson and Company or its affiliates © 2022 BD. All rights reserved.